GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2009

Idera to Obtain $3.8M from Merck KGaA for Progress of Anticancer Agent

  • Idera Pharmaceuticals expects to receive €3.0 million, or about $3.8 million, as a milestone fee from Merck KGaA. The payment is due to the dosing of the first patient with colorectal cancer in a study of IMO-2055 in combination with Erbitux® and Camptosar® in patients.

    This marks the first reported milestone achievement under the $421 million deal inked between the firms in December 2007. Idera anticipates receiving the payment during the second quarter.

    Idera received $40 million at signing of the worldwide licensing and collaboration deal. It covers two toll-like receptor 9 (TLR9) agonists from Idera’s pipeline for the treatment of cancer. Under this partnership, IMO-2055 is also being studied in a Phase Ib trial in combination with Tarceva® and Avastin® in patients with advanced non-small-cell lung cancer.



Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »